FDA
Home Page | CDRH Home Page | Search
| CDRH
A-Z Index | Contact CDRH
|
This is a brief overview of information related to FDA's approval to market this product. See the links below to the Summary of Safety and Effectiveness and product labeling for more complete information on this product, its indications for use, and the basis for FDA's approval.
Product Name: OrthospecTM Extracorporeal Shock Wave Therapy
Applicant: MEDISPEC, LTD.
Address: 12850 Middlebrook Road, Suite 1, Germantown, Maryland
20874
Approval Date: April 1, 2005
Approval Letter: http://www.fda.gov/cdrh/pdf4/p040026a.pdf
What is it?
The OrthospecTM Extracorporeal Shock Wave Therapy device is a non-invasive,
alternative to surgery that uses strong sound waves (extracorporeal
shock wave energy) to relieve heel pain (proximal plantar fasciitis). Proximal
plantar faciitis is an inflammation of the plantar
fascia, the band of connective tissue that stretches from the base of the
toes, across the arch of the foot, and inserts into the heel bone.
How does it work?
The Orthospec™ generates pulses of high pressure sound that travel through
the skin (extracorporeal shock wave therapy) to initiate tissue repair.
The Orthospec™ uses an electro-hydraulic, or “spark gap” method
of creating the shock wave. With this technique, an electrode (spark plug) ignites
an electrical charge within a water-contained, stainless steel, semi-ellipsoid
chamber and contact membrane, evaporating a small portion of the water and creating
a shock wave reflecting outward off the ellipsoid. The shock wave is generated
within the reflector chamber and transmitted through the skin surface of the
patient to the treatment site. Coupling solution is used on both the contact
membrane and the patient's skin during treatments to enhance conductivity.
When is it used?
The OrthospecTM is indicated for the treatment of proximal plantar fasciitis
with or without heel spur in patients:
What will it accomplish?
The Orthospec™ investigation provides sufficient valid scientific data
that demonstrates the Orthospec™ Extracorporeal Shock Wave Therapy modality
to be a safe and effective tool in treating pain caused by Proximal Plantar
Fasciitis. The double-blind study demonstrates clinical success to be unbiased
and encouraging. After the exhaustion of conservative means, surgical plantar
fasciotomy was the practitioners' choice treatment for the reduction of heel
pain. However, Extracorporeal Shock Wave Therapy with the Orthospec™ device
as the data show, offers the patient a more safe and viable option prior to
surgical intervention.
Potential adverse events when using the Orthospec™ device include:
When should it not be used?
The Orthospec™ should not be used:
Additional information: Summary of Safety and Effectiveness and labeling will be available at: http://www.fda.gov/cdrh/pdf4/p040026.html
Other
Plantar faciitis:
http://www.mayoclinic.com/invoke.cfm?objectid=C5D42AB4-5AC4-4CA8-BA3BC6318C19E3CF&dsection=1
http://orthoinfo.aaos.org/fact/thr_report.cfm?Thread_ID=144&topcategory=Foot
Heel Pain: http://www.apma.org/s_apma/doc.asp?CID=371&DID=9408
Updated September 15, 2005
CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page
Center for Devices and Radiological Health / CDRH